| 词条 | Novo Nordisk Foundation |
| 释义 |
| name = Novo Nordisk Foundation | logo = Novo_nordisk_foundation_Logo.png | type = Fund | industry = Life-Sciences | fate = | predecessor = | successor = | founded = {{Start date and age|1989|}} in Denmark | founder = | defunct = | hq_location_city = Hellerup | hq_location_country = Denmark | areas_served = Life-sciences, natural sciences, social sciences | key_people = | products = | owner = | num_employees = | num_employees_year = | parent = | website = {{URL|http://novonordiskfonden.dk/en}} }} The Novo Nordisk Foundation is an international foundation focusing on medical treatment and research. It is situated in Denmark. In 2018 it had a net worth of 49.1 billion USD (331 billion DKK) and is the biggest foundation in Denmark[1]. The Foundation is the primary owner of Novo Nordisk A/S and NovoZymes A/S through its subsidiary company called Novo Holdings A/S.[2] Aside from Novo Nordisk and Novozymes, the foundation is also a major shareholder in more than 75 other companies. The Foundation hands out more than 300 million US dollars each year to research within the fields of Life- and Bioscience.[3] The current chairman of the Novo Nordisk Foundation is Sten Scheibye, while Birgitte Nauntofte is the current CEO.[4] Objectives and purposesThe Novo Nordisk Foundation has a 90-year history. In 1922, Danish professor August Krogh received a permission to produce insulin in the Nordic countries. This sparked the development of high quality diabetes medicine as we know it today, and also the beginning of a Danish business and export venture. At the same time, several foundations were established as a result, all of which has today merged into the Novo Nordisk Foundation.[5] It has since 2010 donated more than 1.3 billion US dollars for research, innovation, treatment, education and humanitarian and social purposes.[6] The Foundation also awards grants for research, primarily at public universities and hospitals. While the main focus lies within biomedicine and biotechnology research, the Foundation also awards grants for research in general practice and family medicine, nursing and art history. The Foundation gets its income from dividends and returns on investments in life-science companies and financial investments made by Novo Holdings A/S, a private limited liability company wholly owned by the Foundation. Novo Holdings A/S is also the holding company in the Novo Group and responsible for managing the Foundation’s assets.[7] In recent years, the Foundation has increased its focus on innovation, diabetes treatment and grants for humanitarian and social purposes. In 2016 the Foundation awarded a little over 420 million US dollars to the Capital Region of Denmark to establish Steno Diabetes Center in Copenhagen, a diabetes treatment and research institution.[8][9] References1. ^https://novonordiskfonden.dk/wp-content/uploads/NNF_ANNUAL_REPORT_2018.pdf {{med-org-stub}}2. ^{{cite journal|url=http://www.nature.com/naturejobs/science/articles/10.1038/nj0470|title=Inside View: Novo Nordisk Foundation|date=4 November 2015|publisher=|doi=10.1038/nj0470}} 3. ^{{cite web|url=http://www.business.dk/medico/novo-fond-fordobler-stoette-til-forskning-og-gode-formaal|title=Novo-fond fordobler støtte til forskning og gode formål|publisher=}} 4. ^http://novonordiskfonden.dk/en/content/board-directors 5. ^http://novonordiskfonden.dk/en/content/history-novo-nordisk-foundation 6. ^https://issuu.com/nnfoundation/docs/nnf_magazine_2015a 7. ^http://novonordiskfonden.dk/en/content/foundations-assets 8. ^https://www.linkedin.com/company/novo-nordisk-fonden 9. ^http://cphpost.dk/news/novo-nordisk-foundation-ready-to-centralise-diabetes-treatment-in-denmark.html 1 : Medical research institutes in Denmark |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。